TriSalus Life Sciences Announces CMS Reimbursement for the TriNav® Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code
14 Dezembro 2023 - 9:00AM
Business Wire
TriSalus Life Sciences® Inc., (Nasdaq: TLSI),
an oncology company integrating its novel delivery technology with
immunotherapy to transform treatment for patients with liver and
pancreatic tumors, is pleased to announce today that the Centers
for Medicare & Medicaid Services (CMS) has created a New
Technology Healthcare Common Procedure Coding System (HCPCS) code
for procedures involving the TriNav® Infusion System. This new
code, HCPCS C9797, has been assigned to the Ambulatory Payment
Classification (APC) 5194 - Level 4 Endovascular Procedures. The
new code will become effective on January 1, 2024, and may be
reported by hospital outpatient departments (HOPDs) and ambulatory
surgical centers (ASCs).
“We want to thank the Centers for Medicare & Medicaid
Services, our congressional supporters, our clinicians, and all the
patients and hospitals that helped to ensure that patients continue
to have uninterrupted access to this important technology," said
Mary Szela, Chief Executive Officer of TriSalus.
About the TriNav Infusion System
TriNav is a flexible, ultra-thin therapy delivery system with
SmartValve technology, a self-expanding, nonocclusive one-way
dynamic microvalve that opens and closes in synchrony with the
patient’s heart to modulate pressure and flow. This system uses the
Pressure-Enabled Drug Delivery approach and has demonstrated the
ability to overcome intratumoral pressure in solid tumors and
potentially improve distribution and penetration of therapy during
Transcatheter Arterial Chemoembolization (TACE) and Transcatheter
Arterial Radioembolization (TARE) procedures. For more information,
please visit www.trinavinfusion.com.
About TriSalus Life Sciences
TriSalus Life Sciences is an oncology company integrating novel
delivery technology with immunotherapy to transform treatment for
patients with liver and pancreatic tumors.
The Company’s platform includes devices that utilize a
proprietary drug delivery technology and a clinical-stage
investigational immunotherapy. The Company’s two FDA-cleared
devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD™)
approach to deliver a range of therapeutics: the TriNav® Infusion
System for hepatic arterial infusion of liver tumors and the
Pancreatic Retrograde Venous Infusion System for pancreatic tumors.
PEDD is a novel delivery approach designed to address the anatomic
limitations of arterial infusion to the pancreas. The PEDD approach
modulates pressure and flow in a manner that delivers more
therapeutic to the tumor and is designed to reduce undesired
delivery to normal tissue, bringing the potential to improve
patient outcomes. SD-101, the Company’s investigational
immunotherapeutic candidate, is designed to improve patient
outcomes by treating the immunosuppressive environment created by
many tumors, which can make current immunotherapies ineffective in
the liver and pancreas. Patient data generated during
Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials
support the hypothesis that SD-101 delivered via PEDD may have
favorable immune effects within the liver and systemically. The
target for SD-101, TLR9, is expressed across cancer types and the
mechanical barriers addressed by PEDD are commonly present as well.
SD-101 delivered by PEDD will be studied across several indications
in an effort to address immune dysfunction and overcome drug
delivery barriers in the liver and pancreas.
In partnership with leading cancer centers across the country –
and by leveraging deep immuno-oncology expertise and inventive
technology development – TriSalus is committed to advancing
innovation that improves outcomes for patients. Learn more at
trisaluslifesci.com and follow us on Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231214139796/en/
For Media and Investor Inquiries: Argot Partners 212.600.1902
TriSalus@argotpartners.com
GraniteShares ETF (NASDAQ:TSLI)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
GraniteShares ETF (NASDAQ:TSLI)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024